References
- Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17(8): 807-21. DOI: 10.1038/s41423-020-0488-6
- Hellmann MD, Ciuleanu TE, Pluzanski A etc. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378 (22):2093-104. DOI: 10.1056/NEJMoa1801946
- Nicholson LB. The immune system. Essays Biochem 2016;60 (3):275-301. DOI: 10.1042/ebc20160017
- Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol 2019;234 (6):8509-21. DOI: 10.1002/jcp.27782
- Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol 2022;13:868695. DOI: 10.3389/fphar.2022.868695
- Dolina JS, Van Braeckel-Budimir N, Thomas GD etc. CD8(+) T cell exhaustion in cancer. Front Immunol 2021;12:715234. DOI: 10.3389/fimmu.2021.715234 From NLM.
- Tan R, Nie M, Long W. The role of B cells in cancer development. Front Oncol 2022;12:958756. DOI: 10.3389/fonc.2022.958756
- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20(11):651-68. DOI: 10.1038/s41577-020-0306-5
- Fenton SE, Saleiro D, Platanias LC. Type I and II interferons in the anti-tumor immune response. Cancers (Basel) 2021;13(5). DOI: 10.3390/cancers13051037
- Chen R, Zhou L. PD-1 signaling pathway in sepsis: Does it have a future? Clin Immunol 2021;229:108742. DOI: 10.1016/j. clim.2021.108742
- Seliger B. Strategies of tumor immune evasion. BioDrugs 2005;19(6):347-354. DOI: 10.2165/00063030-200519060-00002
- Lenocov FR, Paletta AL, Prinz MG etc. Prostaglandin E2 antagonizes TGF-β actions during the differentiation of monocytes into dendritic cells. Front Immunol 2018;9:1441. DOI: 10.3389/fimmu.2018.01441
- Ye SL, Li XY, Zhao K etc. High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study. Medicine (Baltimore) 2017;96 (15):e6472. DOI: 10.1097/md.0000000000006472
- Kawai O, Ishii G, Kubota K etc. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008;113(6);1387-95. DOI: 10.1002/cncr.23712
- Hiraoka K, Miyamoto M, Cho Y etc. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94(2):275-80. DOI: 10.1038/sj.bjc.6602934
- Fumet JD, Richard C, Ledys F etc. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer 2018;119(8):950-60. DOI: 10.1038/s41416-018-0220-9
- Tian C, Lu S, Fan Q etc. Prognostic significance of tumor-infiltrating CD8+ or CD3+ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chin Med J (Engl) 2015;128(1):105-10. DOI: 10.4103/0366-6999.147828
- Wakabayashi O, Yamazaki K, Oizumi S etc. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94(11):1003-9. DOI: 10.1111/j.1349-7006.2003.tb01392.x
- Kikuchi E, Yamazaki K, Torigoe T etc. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007;98(9):1424-30. DOI: 10.1111/j.1349-7006.2007.00558.x
- Rivas-Fuentes S, Salgado-Aguayo A, Arratia-Quijada J etc. Regulation and biological functions of the CX3CL1-CX3CR1 axis and its relevance in solid cancer: A mini-review. J Cancer 2021;12(2):571-83. DOI: 10.7150/jca.47022
- Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J 2019;17:1-13. DOI: 10.1016/j.csbj.2018.11.004
- Rizvi NA, Cho BC, Reinmuth N etc. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Annals of Oncology 2018;29:x40-1. DOI: 10.1093/annonc/mdy511.005 (acccessed 2023/03/30).
- Girardi DM, Niglio SA, Mortazavi A etc. Cabozantinib plus nivolumab phase I expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy. Clin Cancer Res 2022;28(7):1353-62. DOI: 10.1158/1078-0432.Ccr-21-3726
- DeGiglio A, DiFederico A, Nuvola G etc. The landscape of immunotherapy in advanced NSCLC: driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). Curr Oncol Rep 2021;23(11):126. DOI: 10.1007/s11912-021-01124-9
- Reck M, Rodríguez-Abreu D, Robinson AG etc. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774
- Forde PM, Spicer J, Lu S etc. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973-85. DOI: 10.1056/NEJMoa2202170
- Socinski MA, Jotte RM, Capuzzo F etc. Atezolizumab for firstline rreatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378(24):2288-301. DOI: 10.1056/NEJMoa1716948
- Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Pharmacol Ther 2015;153:1-9. DOI: 10.1016/j.pharmthera.2015.05.004
- Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D etc. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012;2012:741741. DOI: 10.1155/2012/741741
Language: English
Page range: 148 - 155
Published on: Nov 7, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Keywords:
Related subjects:
© 2024 Kevin Aristyo, Fariz Nurwidya, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.